Welcome to our dedicated page for Livanova Plc news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova Plc stock.
Overview of LivaNova Plc
LivaNova Plc is a globally recognized medical technology company renowned for its advanced cardiopulmonary solutions and neuromodulation devices. With a history spanning nearly five decades, the company provides essential medical products that address critical healthcare challenges, enhancing outcomes for patients and offering innovative solutions for healthcare professionals.
Core Business and Product Divisions
At the heart of LivaNova's operations is a dedication to developing breakthrough treatments within two major segments. The cardiopulmonary solutions division delivers sophisticated devices such as heart-lung machines and oxygenation equipment that support complex medical procedures. Additionally, its neuromodulation segment focuses on cutting-edge devices designed to treat conditions such as treatment-resistant epilepsy and depression, thereby offering a unique blend of technological innovation and therapeutic efficacy.
Historical Context and Strategic Merger
LivaNova was born from the merger of two influential companies, a union between a US-based firm and an Italian entity. This strategic merger allowed the company to consolidate expertise and divest non-core areas such as cardiac rhythm management and heart valve systems. Today, this refined focus enables LivaNova to concentrate resources on areas where it can deliver both clinical and economic value.
Global Footprint and Market Positioning
Headquartered in the UK, LivaNova operates in more than 100 countries, underpinning its stature as a major player in the global medical technology landscape. The company derives a significant portion of its revenue from the US market, complemented by a strong presence in Europe and other international regions. This diversified geographic reach ensures that LivaNova remains resilient and adaptable in a dynamic global healthcare arena.
Innovation, Expertise, and Industry Insight
With a product portfolio that highlights the integration of innovation and deep sector knowledge, LivaNova stands out through its commitment to enhancing patient outcomes and supporting healthcare infrastructure. The company’s strategic focus on advanced circulatory support and neuromodulation reflects its understanding of the evolving challenges within modern medicine. By consistently leveraging its extensive experience and technological acumen, LivaNova not only responds to current market needs but also anticipates the demands of evolving clinical practices.
Operational Excellence and Commitment to Patient Care
LivaNova is dedicated to delivering products that are both clinically effective and economically viable. Its operations are driven by robust research and development, ensuring that every product meets rigorous quality and safety standards. The company’s neutrally balanced approach makes it a key contributor to healthcare systems worldwide, striving to improve patient care without favoring any one market or region.
Competitive Landscape and Strategic Differentiators
- Focused Specialization: Concentration on high-impact areas like cardiopulmonary and neuromodulation devices where technological breakthroughs are most needed.
- Global Reach: Extensive international presence that facilitates diversified revenue streams and responsiveness to varied market demands.
- Merged Expertise: The combination of experiences from its founding companies provides a unique blend of US and European market insight, strengthening its product development and service delivery.
Conclusion
In summary, LivaNova Plc exemplifies a robust commitment to medical technology innovation and patient-centric solutions. Its refined focus on advanced treatment modalities, supported by an international operational framework and deep industry expertise, makes it a noteworthy entity within the global healthcare ecosystem. The company continues to set benchmarks in clinical efficacy and operational excellence, sustaining its role as an influential player in critical care segments.
LivaNova PLC (NASDAQ:LIVN) has completed the initial closing of its heart valve (HV) business divestiture to Gyrus Capital for €60 million (approx. $73 million). This strategic move allows LivaNova to concentrate on its core cardiovascular and neuromodulation markets. The HV business, expected to generate $70 million in net revenues, will transition 850 employees to Gyrus's newly formed company, CORCYM. Post-divestiture, LivaNova anticipates full-year adjusted EPS between $1.31 to $1.81, reflecting a dilution of approximately $0.09 due to the sale.
LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will present at the UBS Global Healthcare Virtual Conference on May 25 at 8 a.m. ET. This presentation is accessible to the public via a live webcast on the LivaNova website. Interested listeners are advised to log in 10 minutes early for setup. The webcast will be available for replay for 30 days following the event. LivaNova, headquartered in London, is a leading medical technology company dedicated to improving patient lives globally with a workforce of approximately 4,000 employees.
LivaNova PLC (NASDAQ: LIVN) reported a 2.1% increase in worldwide sales for Q1 2021, totaling $247.6 million, but a decline of 0.4% on a constant-currency basis. The company experienced a diluted loss per share of $0.61 under GAAP, while adjusted diluted EPS was $0.35, up from $0.33 in Q1 2020. Notably, Neuromodulation sales rose by 15.7%, while Cardiovascular sales fell by 9.4%. For 2021, LivaNova anticipates net sales growth between 8% and 13%, reaffirming its full-year guidance.
LivaNova PLC (NASDAQ:LIVN) has received FDA 510(k) clearance for B-Capta®, an in-line blood-gas monitoring system integrated into the S5® heart-lung machine. This system enhances monitoring during cardiopulmonary bypass procedures for both adults and children, providing accurate blood gas measurements. B-Capta's features include a no-calibration setup and integration with the S5 HLM, improving workflow for perfusionists. Additionally, LivaNova announced clearance for the upgraded S5 PRO™ HLM with enhanced software and alarm systems.
LivaNova PLC (NASDAQ:LIVN) announced the randomization of the 300th patient in its ANTHEM-HFrEF Pivotal Study, aiming to evaluate Autonomic Regulation Therapy (ART) for heart failure treatment. This FDA-approved study will analyze the effectiveness of Vagus Nerve Stimulation (VNS) on symptoms and clinical outcomes in heart failure patients with reduced ejection fraction. The VITARIA System, designed for ART delivery, may become a first-in-class device if approved. Notable clinical outcomes include symptom relief and reduced hospitalizations.
LivaNova PLC (NASDAQ:LIVN), a leader in medical technology, will host a conference call on April 28, 2021, at 12 p.m. London time (7 a.m. EDT) to discuss its Q1 2021 results. The results will be released prior to the call. Interested listeners can access a live audiocast via the Investors section of LivaNova's website. The dial-in numbers include 844-558-0159 for U.S. and Canada and 236-714-3182 for other regions, with a conference ID of 6493742. A replay will be available for 90 days following the call.
LivaNova PLC (NASDAQ: LIVN) reported a Q4 2020 revenue of $269.6 million, a 6.3% decline compared to Q4 2019, impacted by COVID-19. The diluted loss per share was $5.74, while adjusted EPS was $0.71. Cardiovascular sales fell by 10.1%, with Heart Valves down 27.2%, but Advanced Circulatory Support saw a 50.3% increase. For FY 2020, total sales decreased by 13.8% to $934.2 million. Looking ahead, LivaNova forecasts 2021 sales growth of 8-13% and adjusted EPS between $1.40 and $1.90, despite ongoing COVID-related uncertainties.
LivaNova PLC (NASDAQ:LIVN) will hold a conference call on February 24, 2021, at 1 p.m. London time (8 a.m. EST) to discuss its fourth quarter and full-year 2020 results, which will be released prior to the call. Interested parties can access a live audiocast on LivaNova's Investor Relations website. For phone access, dial 844-239-5285 or 512-961-6524, using conference ID 1290829. A replay will be available for 90 days post-call. LivaNova is a global medical technology company dedicated to innovative healthcare solutions, serving over 100 countries.
LivaNova PLC (NASDAQ:LIVN) will host a virtual symposium titled "Updates and Advances in Neuromodulation" at AES2020 on December 6, 2020, from 6 to 8:30 p.m. ET. The event will feature leading clinicians discussing the role of VNS Therapy in treating drug-resistant epilepsy (DRE) and other disorders. Attendees will explore the economic and healthcare burdens of DRE and learn how VNS Therapy can alleviate these challenges. The symposium is free for AES2020 registrants, and a recording will be available afterward.
LivaNova PLC (NASDAQ:LIVN) has announced a strategic divestiture of its heart valve (HV) business to Gyrus Capital for an enterprise value of €60 million (US$73 million). The deal, unanimously approved by LivaNova's Board of Directors, aims to enhance focus on neuromodulation and cardiovascular platforms. The transaction is expected to be dilutive to earnings per share by approximately 10-15 cents in 2021 and may trigger a non-cash impairment charge of US$200 million to US$225 million. Completion is targeted for the first half of 2021, pending regulatory approvals.
FAQ
What is the current stock price of Livanova Plc (LIVN)?
What is the market cap of Livanova Plc (LIVN)?
What does LivaNova Plc specialize in?
How does LivaNova generate revenue?
What are the core product segments at LivaNova?
How did the merger contribute to LivaNova's current business model?
In which regions does LivaNova operate?
What differentiates LivaNova from its competitors?
How does LivaNova maintain quality and safety in its products?
What is LivaNova's main contribution to healthcare?
